by Admin | May 6, 2021 | Portfolio News
美国圣地亚哥，中国上海、广东松山湖 2021年5月6日，凡恩世生物医药公司（Phanes Therapeutics以下简称“凡恩世”或“公司”）正式宣布完成B轮4千万美元融资。本轮融资由红杉资本中国基金领投，德屹资本、火山石投资、康禧全球投资基金、文周基金跟投，老股东险峰旗云和天使投资人追加投资。生命资本担任本次融资的独家财务顾问。本轮融资将全面加速凡恩世研发管线中多个抗肿瘤单抗及双抗产品的临床转化。...
by Admin | Apr 27, 2021 | Portfolio News
By Antios Therapeutics, Inc. on Tuesday, Apr 27, 2021 Responsible for managing clinical development and the regulatory processes for ATI-2173, an ASPIN, which is in development as part of a potential curative regimen for chronic hepatitis B infection MENDHAM, N.J.,...
by Admin | Apr 22, 2021 | Portfolio News
By Antios Therapeutics, Inc. on Wednesday, Apr 21, 2021 SAVE 1 to evaluate ATI-2173 in combination with tenofovir (TDF) vs. TDF plus placebo SAVE 1 to include cohort of Hepatitis Delta Virus (HDV) co-infected subjects to assess ATI-2173 activity against HDV MENDHAM,...
by Admin | Apr 14, 2021 | Portfolio News
While hepatitis B virus (HBV) infection is avoidable with a vaccine, a host of companies are searching for a cure for the hundreds of thousands in the US who already have it. Antios Therapeutics threw its hat in the ring three years ago, and on Monday...
by Admin | Apr 12, 2021 | Portfolio News
Angus Liu | Apr 12, 2021 7:55am Last year, OncoMyx Therapeutics unveiled preclinical data showing its engineered rabbit pox virus therapy could slow tumor growth in mouse models of melanoma and bone cancer. Now, it’s unveiling more preclinical evidence,...
